id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2185087,7c27bbf3-e77d-4ed0-b064-282b2afe84f4,Q3,"MANATT, PHELPS, AND PHILLIPS",23645,NEKTAR THERAPEUTICS,2018,third_quarter,PHA,FDA oversight of certain pain reliever products,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",108000,,0,0,2018-10-16T10:28:41.107000-04:00